Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma
نویسندگان
چکیده
منابع مشابه
Circulating tumour-derived DNA in metastatic soft tissue sarcoma
Following treatment 40% of soft tissue sarcoma (STS) patients suffer disease recurrence. In certain cancers circulating cell free DNA (cfDNA) and circulating tumour-derived DNA (ctDNA) characteristics correlate closely with disease burden, making them exciting potential sources of biomarkers. Despite this, the circulating nucleic acid characteristics of only 2 STS patients have been reported to...
متن کاملPreoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma.
We report the results of phase I/II studies of preoperative multidisciplinary treatment of 14 patients with soft tissue sarcoma using hyperthermia from November 1990 to April 1995. The preoperative treatment was conducted with thermo-radio-chemotherapy in 11 cases of stage III, and with thermo-radiotherapy as well as thermo-chemotherapy in three cases of stages I and II. Hyperthermia was carrie...
متن کاملCurrent treatment of soft tissue sarcoma.
arcomas are rare tumors, representing only 0.8% of new cancers in the United States. Seventy-six percent arise in soft tissue, with the remainder arising in bone (1). The most common soft tissue type is malignant fibrous histiosarcoma, although this has fallen out of favor recently as a distinct histologic entity (2, 3). Multiple types of soft tissue sarcomas are defined based on the tissue of ...
متن کاملPatient surveillance after treatment for soft-tissue sarcoma.
About 1% of all cancers are soft tissue sarcomas (STS); about 60% of these occur in the extremities. Post-treatment surveillance programs are designed to identify recurrence, new primary cancers, and complications of therapy early enough to increase survival duration and quality of life. The intensity of surveillance varies among surgeons. We hypothesized that geographic factors would account f...
متن کاملLiposomal daunorubicin as treatment for Kaposi’s sarcoma
Anthracycline compounds including daunorubicin are the foundation of many modem chemotherapeutic regimens. However, the side-effects of these compounds can be severe, leading to alopecia, nausea, immune deficiency, and cardiotoxicity. For immunocompromised patients with aggressive Kaposi's sarcoma (KS), these complications often preclude the completion of appropriate chemotherapeutic regimens. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Veterinary and Comparative Oncology
سال: 2012
ISSN: 1476-5810
DOI: 10.1111/j.1476-5829.2012.00319.x